Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H19NO2 |
| Molecular Weight | 209.2848 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCNCC(O)C1=CC=C(O)C=C1
InChI
InChIKey=RDUHXGIIUDVSHR-UHFFFAOYSA-N
InChI=1S/C12H19NO2/c1-2-3-8-13-9-12(15)10-4-6-11(14)7-5-10/h4-7,12-15H,2-3,8-9H2,1H3
| Molecular Formula | C12H19NO2 |
| Molecular Weight | 209.2848 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Bamethan (butyl-sympatol or vasculat) is an adrenaline derivative developed by C. H. Boehringer Sohn. Bamethan shows a depressor action on peripheral blood vessels as a result of the peripheral vasodilating action caused by stimulation of adrenergic beta-receptor. Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | VASCULAT Approved UseBamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tandem mass spectrometry with online high-flow reversed-phase extraction and normal-phase chromatography on silica columns with aqueous-organic mobile phase for quantitation of polar compounds in biological fluids. | 2005 |
|
| Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum. | 2002-06-20 |
|
| The effect of bamethan on cardiovascular response. | 1966-01-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:42:24 GMT 2025
by
admin
on
Wed Apr 02 09:42:24 GMT 2025
|
| Record UNII |
Y08ZFJ9TFK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QC04AA31
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
||
|
WHO-ATC |
C04AA31
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1321
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | RxNorm | ||
|
C76116
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
100000088408
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
223-043-9
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
3703-79-5
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
BAMETHAN
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
DTXSID5046144
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
2292
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
Y08ZFJ9TFK
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
DB13206
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
m2217
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB06096MIG
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
286
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
995
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
C084810
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL1987462
Created by
admin on Wed Apr 02 09:42:24 GMT 2025 , Edited by admin on Wed Apr 02 09:42:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |